Life Cycle Investment Partners Ltd Buys New Shares in UnitedHealth Group Incorporated $UNH

Key Points

• Life Cycle Investment Partners Ltd disclosed a new stake in UnitedHealth Group, buying 144,755 shares valued at about $47.8 million in the fourth quarter.
• Several other institutional investors also added to or initiated positions in UNH, and hedge funds now own 87.86% of the company’s stock, showing continued institutional interest.
• Analysts remain broadly bullish: UBS raised its price target to $460 and reiterated a Buy rating, while recent commentary highlights UNH as a turnaround candidate despite ongoing regulatory concerns around Medicare Advantage overpayments.

Life Cycle Investment Partners Ltd bought a new stake in shares of UnitedHealth Group Incorporated (NYSE:UNH - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 144,755 shares of the healthcare conglomerate's stock, valued at approximately $47,785,000.

A number of other large investors have also made changes to their positions in UNH. Beacon Financial Strategies CORP acquired a new stake in shares of UnitedHealth Group during the fourth quarter valued at approximately $26,000. Anfield Capital Management LLC raised its holdings in shares of UnitedHealth Group by 220.0% during the fourth quarter. Anfield Capital Management LLC now owns 80 shares of the healthcare conglomerate's stock valued at $26,000 after acquiring an additional 55 shares during the period. Joseph Group Capital Management acquired a new stake in shares of UnitedHealth Group during the fourth quarter valued at approximately $27,000. Foster Dykema Cabot & Partners LLC raised its holdings in shares of UnitedHealth Group by 69.4% during the third quarter. Foster Dykema Cabot & Partners LLC now owns 83 shares of the healthcare conglomerate's stock valued at $29,000 after acquiring an additional 34 shares during the period. Finally, 1248 Management LLC acquired a new stake in shares of UnitedHealth Group during the third quarter valued at approximately $29,000. Institutional investors and hedge funds own 87.86% of the company's stock.

Insider Transactions at UnitedHealth Group

In related news, CEO Patrick Hugh Conway sold 800 shares of the firm's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $355.00, for a total value of $284,000.00. Following the transaction, the chief executive officer directly owned 17,805 shares in the company, valued at approximately $6,320,775. This trade represents a 4.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.28% of the company's stock.

Trending Headlines about UnitedHealth Group

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: UBS raised its price target on UnitedHealth Group to $460 from $410 and reiterated a Buy rating, signaling meaningful upside from current levels. Benzinga report on UBS target increase
• Positive Sentiment: UnitedHealth was highlighted by multiple outlets as a high-quality stock and a turnaround bet, with commentary noting that managed care is outgrowing the broader economy and that the company is benefiting from AI adoption in operations. Motley Fool article on AI and turnaround
• Neutral Sentiment: UnitedHealth also appeared in a hedge-fund “high quality stocks” list and a Goldman Sachs conviction-list discussion, which supports the stock’s investment case but does not change fundamentals on its own. InsiderMonkey article on turnaround case
• Negative Sentiment: There is still headline risk around Medicare Advantage overpayments, with a Congressional committee estimating about $7 billion annually in excess payments to private insurers, which could keep regulatory scrutiny on managed-care names like UNH. 247WallSt article on Medicare Advantage overpayments
• Negative Sentiment: Recent discussion also noted that Berkshire-linked selling contributed to a prior stock slide, underscoring that investor sentiment can still turn quickly. Barchart article on Berkshire stake sale

UnitedHealth Group Trading Up 1.6%

Shares of NYSE:UNH opened at $388.42 on Friday. The stock has a market capitalization of $352.74 billion, a PE ratio of 29.34, a P/E/G ratio of 1.67 and a beta of 0.64. UnitedHealth Group Incorporated has a 1 year low of $234.60 and a 1 year high of $404.15. The firm has a fifty day moving average price of $326.93 and a 200 day moving average price of $319.63. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 0.69.

UnitedHealth Group (NYSE:UNH - Get Free Report) last issued its quarterly earnings data on Tuesday, April 21st. The healthcare conglomerate reported $7.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.76 by $0.47. The firm had revenue of $111.65 billion during the quarter, compared to analysts' expectations of $109.84 billion. UnitedHealth Group had a net margin of 2.68% and a return on equity of 14.65%. UnitedHealth Group's revenue for the quarter was up 2.0% on a year-over-year basis. During the same period in the prior year, the company posted $7.20 earnings per share. UnitedHealth Group has set its FY 2026 guidance at 18.250- EPS. Analysts expect that UnitedHealth Group Incorporated will post 18.29 EPS for the current fiscal year.

UnitedHealth Group Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 17th. Investors of record on Monday, March 9th were paid a $2.21 dividend. The ex-dividend date was Monday, March 9th. This represents a $8.84 dividend on an annualized basis and a yield of 2.3%. UnitedHealth Group's dividend payout ratio (DPR) is presently 66.77%.

Analyst Upgrades and Downgrades

UNH has been the topic of a number of recent analyst reports. Piper Sandler restated an "overweight" rating on shares of UnitedHealth Group in a report on Tuesday, January 27th. JPMorgan Chase & Co. upped their price objective on shares of UnitedHealth Group from $389.00 to $420.00 and gave the company an "overweight" rating in a research note on Tuesday, April 28th. UBS Group upped their price objective on shares of UnitedHealth Group from $410.00 to $460.00 and gave the company a "buy" rating in a research note on Friday. Sanford C. Bernstein upped their price objective on shares of UnitedHealth Group from $405.00 to $411.00 and gave the company an "outperform" rating in a research note on Tuesday, April 7th. Finally, Barclays lifted their price target on UnitedHealth Group from $327.00 to $373.00 and gave the company an "overweight" rating in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, UnitedHealth Group presently has a consensus rating of "Moderate Buy" and a consensus target price of $387.57.

About UnitedHealth Group

UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

UnitedHealthcare is the company's benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.

Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.